# US 2021/0330736 A1 · Use of a pde11 or pde2 inhibitor for the treatment of parkinson's disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330736 A1
- Document ID: US20210330736A1
- Status: Published application
- Kind: A1
- Application number: 17/271,978
- Filed: 2019-09-05
- Published: 2021-10-28
- Earliest claimed: 2018-09-05
- Assignees: Universiteit Van Amsterdam
- Applicants: Universiteit Van Amsterdam
- Inventors: Marten Piet SMIDT; Lars Philip VAN DER HEIDE
- Web page: https://patentgrep.com/patent/US20210330736A1

## CPC

- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/52: Purines, e.g. adenine
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61K 38/005: {Enzyme inhibitors (protease inhibitors A61K38/55)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

In embodiments the invention relates to means and methods for the treatment of Parkinson's disease. In some embodiments the means and methods involve a PDE2 inhibitor, a PDE11 inhibitor or a combination thereof, optionally together with a GUCY2C agonist.

## Claims

### Claim at position 1

1-7. (canceled)

### Claim 8

A method of increasing phosphorylation of the serine residue at position 40 of human tyrosine hydroxylase (S40 Th) by a dopaminergic cell, the method comprising contacting said cell with a PDE11 inhibitor, a PDE2 inhibitor or a combination thereof

### Claim 9

A method of increasing dopamine production by a dopaminergic cell, the method comprising contacting said cell with a PDE11 inhibitor, a PDE2 inhibitor or a combination thereof

### Claim 10 (depends on 8)

The method of claim 8, further comprising contacting said cell with a GUCY2C agonist.

### Claim 11

A method of treatment of an individual that has Parkinson's disease, or is at risk of developing the disease, the method comprising administering a PDE11 inhibitor, a PDE2 inhibitor or a combination thereof to the individual in need thereof.

### Claim 12

A GUCY2C agonist comprising the sequence NDDCELCVNVACTGCLL; NDCCELCCNVACTGCL; NDDCELCVNVVCTGCL; QEECEL[Abu]INMACTGY; QEECELCINMACTGCL; NTFYCCELCCNPACAGCY; NTFYCCELCCAPACTGCY; or NTFYCCELCCNPaCAGCY.

### Claim 13 (depends on 11)

The method of claim 11, wherein the treatment further comprises a guanylate cyclase 2C receptor (GUCY2C) agonist.

### Claim 14 (depends on 11)

The method of claim 11, wherein the individual has Parkinson's disease stage 1, 2, 3 or 4.

### Claim 15 (depends on 11)

The method of claim 11, wherein the PDE2 inhibitor is EHNA (erythro-9-(2-hydroxy-3-nonyl)adenine); BAY 60-7550 (2-[(3,4-Dimethoxyphenyl)methyl]-7-[(2R,3R)-2-hydroxy-6-phenylhexan-3-yl]-5-methyl-1H-imidazo[5,1-f][1,2,4]triazin-4-one); PDP (9-(6-phenyl-2-oxohex-3-yl)-2-(3,4-dimethoxybenzyl)-purin-6-one; or oxindole (2,3-dihydroindol-2-on).

### Claim 16 (depends on 11)

The method of claim 11, wherein the PDE11 inhibitor is BC11-15; BC11-19; BC11-28; BC11-38; BC11-38-1; BC11-38-2; BC11-38-3 or BC11-38-4.

### Claim 17

The method of claim, wherein the GUCY2C agonist is guanylin or a functional derivative thereof.

### Claim 18 (depends on 13)

The method of claim 13, wherein the GUCY2C agonist comprises the sequence NDDCELCVNVACTGCLL; NDCCELCCNVACTGCL; NDDCELCVNVVCTGCL; QEECEL[Abu]INMACTGY; QEECELCINMACTGCL; NTFYCCELCCNPACAGCY; NTFYCCELCCAPACTGCY; or NTFYCCELCCNPaCAGCY.
